Cover Image

Glucagon‐Like Peptide‐1 Receptor Agonists and Anesthesia—Are We Clearer on the Correct Approach?

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Author:	Zachary Bloomgarden
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Journal of Diabetes
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

An Update on GLP‐1 Receptor Agonists
by: Zachary Bloomgarden
Published: (2025)

Sex Differences in the Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta‐Analysis
by: Yucheng Yang, et al.
Published: (2025)

Beyond GLP ‐1
by: Zachary Bloomgarden
Published: (2026)

Updates in Type 1 Diabetes ( T1D ): What Recent Findings Might Mean for Treatment and Prevention Strategies
by: Zachary Bloomgarden
Published: (2026)

What will we see in diabetes in the next 10 years?
by: Zachary T. Bloomgarden
Published: (2024)

The 2023 WCIRDC: Obesity
by: Zachary T. Bloomgarden
Published: (2024)

What is in a name and other peeves
by: Zachary Bloomgarden
Published: (2024)

Diabetic kidney disease—Recent updates
by: Zachary Bloomgarden
Published: (2024)

Imelda Lee—A memorial note
by: Zachary Bloomgarden
Published: (2024)

Recent Articles—Skeletal Muscle and Other Topics in Diabetes
by: Zachary Bloomgarden
Published: (2025)

Cardiovascular Disease, Cancer and Dementia in Diabetes: 20‐Year Trends Will Necessitate New Treatment Priorities
by: Zachary T. Bloomgarden
Published: (2026)

Effect of Glucagon‐Like Peptide‐1 Receptor Agonists on Renal and Cardiovascular Risk Factors in Patients With Type 2 Diabetes Mellitus: A Retrospective Study
by: Daniel Yuan, et al.
Published: (2025)

Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review
by: Timothy H. Chan, et al.
Published: (2026)

Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study
by: Arvid Engström, et al.
Published: (2026)

Diabetic Kidney Disease Update
by: Christian Mende, et al.
Published: (2025)

Efficacy and Safety of Glucagon‐Like Peptide‐1 Receptor Agonists Following Bariatric Surgery: A Systematic Review and Meta‐Analysis
by: Abdur Rafay Bilal, et al.
Published: (2026)

Effects of Glucagon‐Like Peptide‐1 Receptor Agonist on Bone Mineral Density and Bone Turnover Markers: A Meta‐Analysis
by: Hee‐Ju Kim, et al.
Published: (2024)

Association of Glucagon‐Like Peptide‐1 Receptor Agonist Use With Risk of Psychiatric Disorders: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
by: Shumeng Han, et al.
Published: (2026)

Long‐Term Glucagon‐Like Peptide 1 Receptor Agonist Use Is Not Associated With Increased Risk of Thyroid Cancer in Adults With Type 2 Diabetes
by: Rena Pollack, et al.
Published: (2025)

Deciphering the connection: Diabetes, pericyte dysfunction, and their impact on cardiovascular health
by: Robert Chilton, et al.
Published: (2024)

Kidney Outcomes With Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Glucose‐Lowering Agents in People With Type 2 Diabetes: A Systematic Review and Meta‐Analysis of Real‐World Data
by: Alisa Fishkin, et al.
Published: (2025)

Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta‐Analysis of Clinical Trials
by: Celina R. Andonie, et al.
Published: (2025)

Ensuring the Appropriate Use of Glucagon‐Like Peptide‐1 Receptor Agonists
by: Kenneth Todd Moore, et al.
Published: (2024)

Comparison of Sodium‐Glucose Cotransporter 2 Inhibitors Versus Glucagon‐Like Peptide‐1 Receptor Agonists and Risks of Osteoarthritis and Arthroplasty in Patients With Type 2 Diabetes Mellitus: A Propensity Score‐Matched Cohorts Retrospective Study
by: Yu‐Chi Su, et al.
Published: (2025)

Glucagon‐Like Peptide‐1 Receptor Agonists: Are We Swapping One Public Health Crisis for Another?
by: Danielle Ní Chróinín, et al.
Published: (2026)

Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta‐Analysis of Randomised Controlled Trials
by: Ayah Abulehia, et al.
Published: (2026)

Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon‐Like Peptide‐1 Receptor Agonist Versus a Fixed‐Ratio Combination Therapy: A Japanese Database Study
by: Takeshi Miyatsuka, et al.
Published: (2026)

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
by: Richard J. MacIsaac, et al.
Published: (2024)

Efficacy of GLP‐1 Receptor Agonist‐Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials
by: Yue Yin, et al.
Published: (2025)

Comparison of GLP‐1 Receptor Agonists, SGLT‐2 Inhibitors, and DPP‐4 Inhibitors as an Add‐On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review
by: Sanbao Chai, et al.
Published: (2024)

Impact of Glucagon‐Like Peptide‐1 Receptor Agonists on Proteinuria in Kidney Transplant Recipients
by: Stephanie Shabanowitz, et al.
Published: (2026)

Time‐Related Biases in Observational Studies of GLP ‐1 Agonists and Cancer Risk
by: Fei Lu
Published: (2026)

Reply: Time‐Related Biases in Observational Studies of GLP ‐1 Agonists and Cancer Risk
by: Zhiyuan Cheng, et al.
Published: (2026)

Impact of Preoperative Glucagon‐Like Peptide‐1 Receptor Agonist on Outcomes Following Major Surgery
by: Zayed Rashid, et al.
Published: (2025)

Usefulness of Once‐Weekly GLP‐1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study
by: Tomohiko Kimura, et al.
Published: (2024)

Targeting central pathway of Glucose‐Dependent Insulinotropic Polypeptide, Glucagon and Glucagon‐like Peptide‐1 for metabolic regulation in obesity and type 2 diabetes
by: Zhimin Xu, et al.
Published: (2024)

Interpreting Pregnancy Risk After GLP ‐1 Receptor Agonists Discontinuation
by: Roberta Scairati, et al.
Published: (2026)

The Potential of SARMs and Antimyostatin Agents in Addressing Lean Body Mass Loss From GLP‐1 Agonists: A Literature Review
by: Jimmy Wen, et al.
Published: (2025)

Glucagon‐like‐peptide‐1 receptor agonists versus dipeptidyl peptidase‐4 inhibitors and cardiovascular outcomes in diabetes in relation to achieved glycemic control. A Danish nationwide study
by: Bochra Zareini, et al.
Published: (2024)

Association of GLP ‐1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program
by: Inyoung Hwang, et al.
Published: (2026)